Biography:

Mahableshwar Hegde, PhD in biochemistry, has over 30 years post garduate teaching experience, guiding M.Sc, M.Phil, PhD students at Pune University and for the last 20 years has passionately working for omega-3 nutritional security, by establishing a “Center for Innovation in Nutrition Health and Disease (CINHD)” and “Real World Nutrition Laboratory Foundation (RWNLF)” in Bharati Vidyapeeth (deemed to be)University Pune, to validate the innovative omega-3 enriched products throgh FLAX BIOVILLAGE” concept devloped by him. He has published extensively and edited a book “OMEGA 3 FATTY ACID” keys to nutritional health, published by Springer International.

Abstract:

Biography:

Bandar Manawer Al Harbi is working as Assistant Director of Pharmacy for Material Management at Prince Sultan Military Medical City. His current research is in diabetes at DMU University, UK. He is an Adjunct Clinical Assistant Professor at King Saud University, College of Pharmacy and Director of Pharmacy and Director of Central Sterile Supplies Department, PSMMC, Director of Medical Supplies and Purchasing, PSMMC. He is the Chairman of the fi rst International Sterilization Symposium, Instructor of Purchasing Material Management/CSSD course. He is the active Member of American Society of Health System Pharmacist (ASHP) and Saudi Commission for Health Care Specialties. He has participated in many conferences globally

Abstract:

Introduction & Aim: Pre-diabetes describes a condition whereby an individual’s level of blood glucose is above normal level, though not high enough to warrant them a T2D diagnosis. Th e condition is classifi ed into two categories, Impaired Glucose Tolerance (IGT) where blood glucose levels are above the normal 2 hours aft er glucose loading in the oral glucose tolerance test but not so high to warrant the classifi cation as diabetes. Th e other is Impaired Fasting Glucose (IFG) where blood glucose have risen to a fasting state but yet again, not so high to warrant the classifi cation as diabetes. Physical exercise improves BG homeostasis but the extent to which exercise is eff ective strategy as primary prevention mechanism for people whom at risk to develop diabetes is not fully understood. Th e study aims to examine the eff ects of 6-weekes moderate-intensity combined aerobic and resistance exercise program in preventing or delaying the onset of diabetes for subjects at risk compared to sedentary non-diabetic individuals. Method: 20 subjects of a sedentary lifestyle, diagnosed with either pre-diabetes or at risk to developed T2D (PRE-D) and 5 subjects were sedentary healthy individuals (ND) met the inclusion criteria. Both PRE-D and ND have been asked to complete 6-weeks of moderate-intensity combined aerobic and resistance exercise for 60 minutes on two days/week. Each exercise session consists of a combined exercise protocol of 30 minutes of resistance exercise (3 sets of 10 repetitions) followed by 20 minutes cycling. Th e primary outcome is to concentrate on metabolic results, such as improved HbA1c, blood pressure, heart rate, 1-repition max, lipid profi le (reduction in total cholesterol, low density lipoproteins, triglycerides or increase high density lipoproteins) and improvements in insulin sensitivity determined by responses to oral glucose tolerance tests on independent days. Result: Th ere were signifi cant reduction (p=0.00) on the HbA1c aft er applying of 6 weeks’ combination exercise intervention in both groups comparing to baseline. OGTT indicated signifi cant diff erences between pre-exercise and post 12th exercise session in both groups with p=0.01. BG concentrations.

Biography:

Najmul Islam is currently working as a Professor in Biochemistry, Faculty of Medicine, Aligarh Muslim University, India. He was the Former Head of the Department of Biochemistry. He has worked for four years in the Division of Infectious Diseases and Department of Rheumatology, Case Eastern Reserve University, Cleveland, Ohio, USA. He was Joint Secretary in 2012-13, Vice President, 2014 and President, 2015 of Indian Academy of Biomedical Sciences, Lucknow. He has published more than 70 papers/articles in reputed journals and has been serving as an Editorial Board Member of repute.

Abstract:

Introduction & Aim: Th e relationship between Reactive Oxygen Species (ROS) and various diseases like metabolic cardiac disorders, osteoporosis, tuberculosis and cancer and are well documented. Th e present study involves the employment of a natural compound namely allicin from garlic having anti-oxidant and anti-infl ammatory properties with proven health benefi ts. Our preliminary observations appear to possibly provide some scientifi c input that may be useful in the management of Ischemic Heart Disease (IHD), osteoporosis, tuberculosis and cancer. Method: Peripheral Blood Mononuclear Cells (PBMC’s) were isolated by density gradient method from blood of patients with Ischemic Heart Disease (IHD), osteoporosis, tuberculosis and cancer (n=20 each) and were employed in culture studies with and without of varying does of allicin (0-500 ng/ml). Th e 24 hr cultures were probed for CK, sTNF-alpha, sRANKL levels as well as for Glutathione Peroxidase (GPx) activity. Result: Cells were collected aft er 24 hours with and without allicin (0-500 ng/ml; n=20 each). An appreciably suppressed GPx activity was recorded in cell cultures of patient’s with IHD, osteoporosis, tuberculosis and cancer when compared to samples of healthy controls where the GPx data refl ects upon the compromised defense system in patients with Ischemic Heart Disease (IHD). On the contrary, treatment or co-culturing with varying doses of allicin (0-500 ng/ml) exhibited a remarkable degree of amelioration in GPx activity in cells of all the above four types of diseased patients. Next, the ELISA data showed that the 24 hr culture supernatants of untreated patients cells were having augmented expressions of sTNF-alpha, which upon co-culturing with 500 ng/ml of allicin resulted in an appreciable degree of downregulation/suppression in the expressions of sTNF-alpha in cells of all the above four types of diseased patients. Cultures from all patient types exhibited a dose dependent suppression with allicin. Similarly, in IHD patients, in comparison to untreated controls, a dose dependent decrease in CK levels were observed in cultures receiving allicin (0-500 ng/ml; n=10). Also, in cell cultures from osteoporosis patients, allicin (0-500 ng/ ml), showed an appreciable degree of downregulation in sRANKL. Conclusion: Th e encouraging preliminary data suggested that in-depth studies are required at the molecular level, which in turn, may provide information for possibly employing allicin as potential adjunct in the management of Ischemic Heart Disease (IHD), osteoporosis, tuberculosis and cancer. repute.

Biography:

Samih Abed Odhaib has completed his PhD from Nahrain Medical School. He is a Fellow of Iraqi Board of Medical Specialization (Internal Medicine) FIBMS, Member of American College of Physician (ACP), Member of American Association of Clinical Endocrinologist (AACE).

Abstract:

The T2DM in adulthood is strongly related to weight gain and excessive accumulation of pancreatic and hepatic fat. It is very uncommon to have remission without bariatric surgery. Acute negative energy balance can reverse the twin defects of beta cell failure and insulin resistance alone with diet restriction to around 700 kcal that results in decreased pancreatic and liver triacylglycerol stores. Weight loss of at least 10-15 kg has been shown to achieve euglycemia in people with shortduration T2DM for at least 12 months. A 48-year old diabetic male presented to Faiha Specialized Diabetes, Endocrine and Metabolism Center two years ago with very poorly controlled T2DM that was diagnosed more than 3 years ago, along with severe hypertension and marked dyslipidemia. He underwent complete remission of his diabetes aft er losing 18 kg of his original weight (58 kg), with a very good euglycemia measures, on no treatment at all for the last two years. Th e eff ect that extends to make him have normal blood pressure and normal lipid profi le, with decreased cardiovascular risk from 26% to be less than 1%.

Biography:

Archana Arora is a Registered Dietitian and has been practicing for more than 20 years in the fi tness, healthcare, wellness and catering industries. She has completed her Masters in Food and Nutrition in 1995 followed by an internship at the All India Institute of Medical Sciences, New Delhi. Currently, she is working as a Senior Dietitian and Health Coach at NU Foods, Dubai.

Abstract:

Way of life is central to human wellbeing, from what we eat, how much we move, what we think, what chemicals we are exposed to, how we deal with our emotions and the quality of sleep and the list goes on. Epigenetics (a change in our genetic activity without changing our genetic code) shows that genetics is only 30% of the health equation, with lifestyle choices being 70%. But do we realize it is the wrong lifestyle choices we make, that prepare our body for disease and lead to death. Self-analyzation, willingness to change, continuous wellness journey with trustworthy professional, self-effi cacy evolution (people’s belief that they have the ability to perform particular behaviors) and perseverance can be the most obvious drivers of signifi cant health evolution in your life. With practice, we can enhance our wellbeing and achieve a state of balance and contentment. Lifestyle choices that we make are the basis of our well-being and enhanced quality of life.

Biography:

Ragdah A Hamid has completed her Bachelor’s degree in Nursing from The University of Jordan and her Post Graduation Diploma in Diabetes Primary Care from St. Geroge University School of Medicine. She is the Diabetes Nurse Educator in King Saud Medical City, Riyadh.

Abstract:

Introduction: Th e Diabetes Nurse Educator (CDE) role in King Saud Medical City is a new approach to improving the quality of staff competencies in the care of patients with diabetes. Th e Diabetes Nurse Educator is an advanced nursing clinician with a focused expert practice area who works to improve the care at the bedside by combining roles as clinician, consultant, researcher, educator, and manager. Th e Diabetes Nurse Educator has specific responsibilities in serving as an expert in the specialty, ensuring the incorporation of evidence-based practices, promoting research, evaluating the staff nurses’ practice, providing continuous learning opportunities, and promoting critical thinking and problem solving. Location/Setting: King Saud Medical City-Riyadh, Endocrinology Department – Diabetes Division Outpatient Clinic and In-patient Units- General Hospital Objective: Th e goal of implementing the Diabetes Nurse Educator role at King Saud Medical City (KSMC) was to improve the quality, safety, eff ectiveness, and effi ciency of staff nurses caring for patients with diabetes. Activities: Th e Diabetes Nurse Educator activities include: Th e Development and Implementation of Educational Programs for Staff Nurses, Participating in Staff General Nursing Orientation Program (GNO),Organizing Hospital Continuous Nurse Education (HCNE) and Unit Continuous Nurse Education (UCNE) activities in clinical areas Developing Multidisciplinary Educational Programs through the year with other Health Care Professionals, Leading Nursing Grand Rounds and In-service Education, Provide Clinical Resource and Consultation to Staff Nurses in Collaboration with the Endocrine Team, Developing and Implementing Written Protocols and Order Sets in Coordination with Endocrine Team, Working within the community to promote health care including education and training for Community to Support Workers Conclusion: Th e CDE plays an integral role in the prevention, diagnosis and adequate management of diabetes. Th is specialist role can increase skills, knowledge and confidence, as well as support and empower staff nurses who deal with diabetic patients and help to reduce the chances of developing further complications of the disease.

Biography:

Nicolas Wiernsperger is a Physiologist and has completed his PhD in Neurophysiology from University Basel, Switzerland. He has worked as the Head of Department of Brain Microcirculation at Novartis and also he was the Head of International Pharmacological Development at Lipha/Merck KgA in Lyon. He was also Head of a Private/ Public Research Unit on Diabetic Micro vascular Complications at Lyon University. He has been an Author/Co-author of about 150 publications and 2 scientifi c books. He has also worked as a Visiting Professor at several universities. He is presently a Private Consultant for Pathophysiological and Pharmacological aspects of cardio metabolic diseases.

Abstract:

Obesity is a hallmark of pre-diabetes with a conversion rate of close to 10%. However, recent large-scale clinical observations tell us that non-diabetic obesity (metabolic syndrome) is as dangerous as established diabetes for macro angiopathy. Obesity is becoming a huge worldwide health problem and actual lifestyle measures are of limited effi cacy, in addition to be diffi cult to sustain. Th erefore, complementary dietary measures are highly suitable. Among these, garlic and more particularly aged (black) garlic, is of particular potential interest based on its pharmacological properties which target most of the individual parameters causally involved in obesity development. Although a lot has still to be learned and precised about ideal composition and dosage for humans, animal research shows promising benefi cial eff ects. A recent trial with concentrated aged garlic extract has demonstrated impressive loss of weight over short treatment duration in high fat/high sucrose chronic fed rats. Several mechanisms, including central eff ects in hypothalamus, have emerged.

Biography:

Maha Mohammed Arnous has completed his MD degree from School of Medicine in King Fahad Medical City in Riyadh, Saudi Arabia. She is the Senior Resident of Community and Family Medicine at Security Forced Hospital. She is very active in clinical research of diabetes care and prevention.

Abstract:

Background: Many studies have provided evidence for an increased risk of atrial fi brillation among diabetic patients as compared to the non-diabetic population. It is also well known that diabetes predisposes a person to an increased risk of diabetic nephropathy. A few reviews and studies have hinted towards an increased risk of atrial fi brillation among diabetic nephropathy patients. Aim: To conduct a meta-analysis to explore if there is an association between diabetic nephropathy and atrial fi brillation. Methods: Th e available literature was searched for relevant studies from the period of January 1995 to October 2018. Th e following quality assessment criterion were considered for study shortlisting: Clearly defi ned comparison groups, same outcome measured in both comparison groups, known confounders addressed and a suffi ciently long and complete (more than 80%) follow-up of patients. Two independent reviewers searched the databases, formed their search strategies and fi nalized the studies. Data was analyzed to obtain a summary odds ratio along with a forest plot by Cochrane’s RevMan 5.3. Results: Only four studies were found to meet the inclusion criterion for this meta-analysis (total number of study participants: 307330, diabetic nephropathy patients: 22855). Of these, two were retrospective cross-sectional studies, one was a prospective cohort study and one was a case control study. Th ree studies had provided the odds ratio as the measure of eff ect (two retrospective cross-sectional studies and one case control study), with the one cohort study reporting the hazards ratio as the measure of eff ect. Th erefore, the meta-analysis was done excluding the cohort study. Th e summary odds ratio in the present study was 1.32 (0.80-2.18), which was not statistically signifi cant. Due to large heterogeneity among the included studies and their small sample sizes, it was found that the summary estimate shift ed towards the null value. Conclusion: Th e present meta-analysis found no signifi cant association between atrial fi brillation and diabetic nephropathy. However more studies with large sample sizes are required to strengthen the evidence for an association.

Biography:

Sultan Al Dalbhi has completed his Clinical Fellowship in Nephrology and Clinical Research Associate degree from School of Medicine in McMaster University and University of Toronto. He is currently a Consultant Nephrologist at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. He is very active as Clinical Researcher in diabetic nephropathy care and prevention.

Abstract:

Treatment with Renin Angiotensin Aldosterone System (RAAS) blockade including Angiotensin-Converting Enzyme inhibitors (ACEis) and Angiotensin II Receptor Blockers (ARBs) have been shown to improve clinical outcomes. However, recent contrasting evidence regarding the dual RAAS blockade has also been presented. Very few studies have investigated the eff ectiveness of this dual blockade among Diabetic Nephropathy (DN) patients in association with albuminuria or proteinuria that is why we did this review. A review of Randomized Controlled Trial (RCT) studies (n=45) reporting on the dose response analysis among DN patients using the RAAS blockade and other monotherapies over a 25-year period was performed. Overall, 45 studies of DN patients (n=18,628) with albuminuria or proteinuria were included. An association between dual RAAS blockade and DN was observed in which 18 of the 45 datasets revealed that combination therapies were eff ective among DN patients. Although there was a decline in albuminuria (mean diff erence: -19.93 mcg/L; 95% CI -50.32-10.47; I2=87.8%, p=0.000) and a slight decline in proteinuria (mean diff erence: -0.19 mg/mmol; 95% CI -2.32-2.70; I2=99.2%, p=0.000) with dual RAAS blockade combination therapy, these results demonstrated high heterogeneity among studies with non-signifi cant eff ects. Based on this study, it appears that dual RAAS blockade (or a combination of therapies) is a neutral treatment for patients with DN presenting with symptoms of albuminuria and/or proteinuria. Th erefore, other factors must be considered when recommending therapies for DN patients.